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Patient-Specific	Inference	of	Average	Glucose	from	
Glycated	Hemoglobin:	Toward	Personalized	Diabetic	
Monitoring	with	Precision	Laboratory	Medicine	
Roy	Malka1,2,	David	M.	Nathan3	and	John	M	Higgins1,2	
1Center for Systems Biology and Department of Pathology, Massachusetts General Hospital, 
Boston, MA, USA, 2Department of Systems Biology, Harvard Medical School, Boston, MA, 
USA, 3Diabetes Center, Massachusetts General Hospital, Boston, MA, USA 	Glycated	hemoglobin	(HbA1c)	is	the	gold	standard	for	monitoring	chronic	glucose	control	in	diabetes,	providing	estimate	for	a	patient’s	average	plasma	glucose	concentration	over	the	prior	~120	days.		Patients	with	elevated	HbA1c	have	significantly	increased	risks	of	morbidity	and	mortality.		Despite	the	clear	link	between	high	HbA1c,	elevated	average	glucose	(AG),	and	poor	clinical	outcomes,	the	relationship	between	average	glucose	and	HbA1c	is	not	fully	understood.		Some	patients	with	identical	HbA1c	have	average	glucose	levels	that	vary	by	33%,	and	some	patients	with	the	same	average	glucose	have	HbA1c	levels	that	vary	by	26%.		If	we	could	control	these	sources	of	variation	for	individual	patients,	we	could	provide	precise,	personalized	diabetic	monitoring	that	would	greatly	improve	patient	outcomes	for	one	of	the	largest	healthcare	burdens.	We	demonstrate	here	that	RBC	lifespan	is	the	single	most	important	source	of	variability	in	the	HbA1c-AG	relation.		
	We	combine	deterministic	modeling	of	hemoglobin	glycation	(as	first	reported	by	Bunn	et	al.	1976)	with	stochastic	modeling	of	the	RBC	lifespan	variability	(with	measurements	from	Khera	et	al.	2015).	The	model	is	used	to	demonstrate	the	contributions	of	the	measured	variation	in	RBC	lifespan	to	the	variation	in	HbA1c	in	addition	to	contribution	of	average	glucose.		By	combining	a	biochemical	model	of	glycation	kinetics	with	a	stochastic	analysis	of	RBC	lifespan	variability,	we	can	reconstruct	the	known	linear	regression	relation	between	average	plasma	glucose	level	and	measured	HbA1c.		Our	results	show	consistency	of	the	measured	HbA1c	and	averaged	glucose	from	the	A1c-Derived	Average	Glucose	(ADAG)	Study	Group	(N=507,	Nathan	et	al.	2008)	with	our	model	simulation.	Data	from	the	Diabetic	Control	and	Complications	Trial	(N=1439,	DCCT	1993)	reveal	similar	consistency	between	the	measurements	and	the	model	simulations.		The	model	demonstrates	that	documented	variability	in	the	human	RBC	lifespan	is	sufficient	to	explain	all	of	the	observed	variability	in	the	relation	between	HbA1c	and	average	glucose.		Our	combined	modeling	of	hemoglobin	glycation	and	RBC	lifespan	variation	strongly	supports	no	significant	difference	in	the	glucose-independent	glycation	rate	between	individuals,	because	any	differences	in	glycation	rate	would	need	to	be	almost	perfectly	anti-correlated	with	variability	in	the	RBC	lifespan	for	those	individuals.			We	can	use	the	model	to	estimate	the	patient’s	average	RBC	lifespan	from	a	measurement	of	HbA1c	and	average	glucose.		This	patient-specific	estimate	of	RBC	age	can	then	be	combined	with	future	HbA1c	measurements	to	provide	more	accurate	estimate	of	average	glucose	and	thus	diabetic	monitoring	personalized	for	each	individual	patient.								
